Athersys, Inc. (ATHX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATHX POWR Grades
- Growth is the dimension where ATHX ranks best; there it ranks ahead of 59.16% of US stocks.
- ATHX's strongest trending metric is Growth; it's been moving up over the last 148 days.
- ATHX's current lowest rank is in the Stability metric (where it is better than 1.56% of US stocks).
ATHX Stock Summary
- ATHX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.65% of US stocks.
- The volatility of ATHERSYS INC's share price is greater than that of 98.37% US stocks with at least 200 days of trading history.
- ATHERSYS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -182.53%, greater than the shareholder yield of merely 3.15% of stocks in our set.
- Stocks that are quantitatively similar to ATHX, based on their financial statements, market capitalization, and price volatility, are NVAX, GRNA, HGEN, ARDS, and ALT.
- Visit ATHX's SEC page to see the company's official filings. To visit the company's web site, go to www.athersys.com.
ATHX Valuation Summary
- In comparison to the median Healthcare stock, ATHX's price/sales ratio is 36.59% higher, now standing at 2.8.
- ATHX's price/sales ratio has moved up 2.1 over the prior 190 months.
Below are key valuation metrics over time for ATHX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ATHX | 2023-01-20 | 2.8 | -1.0 | -0.2 | -0.1 |
| ATHX | 2023-01-19 | 2.8 | -1.0 | -0.2 | -0.1 |
| ATHX | 2023-01-18 | 2.7 | -1.0 | -0.2 | -0.1 |
| ATHX | 2023-01-17 | 2.8 | -1.0 | -0.2 | -0.2 |
| ATHX | 2023-01-13 | 2.7 | -1.0 | -0.2 | -0.1 |
| ATHX | 2023-01-12 | 2.6 | -0.9 | -0.2 | -0.1 |
ATHX Growth Metrics
- Its 5 year cash and equivalents growth rate is now at 2.35%.
- Its 5 year net income to common stockholders growth rate is now at -83.8%.
- Its 4 year revenue growth rate is now at 24.68%.
The table below shows ATHX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 6.015 | -66.324 | -81.244 |
| 2022-06-30 | 10.742 | -75.597 | -83.752 |
| 2022-03-31 | 8.426 | -79.26 | -82.703 |
| 2021-12-31 | 5.514 | -76.185 | -86.955 |
| 2021-09-30 | 6.062 | -74.126 | -87.45 |
| 2021-06-30 | 1.356 | -74.157 | -93.816 |
ATHX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ATHX has a Quality Grade of C, ranking ahead of 38.11% of graded US stocks.
- ATHX's asset turnover comes in at 0.02 -- ranking 368th of 682 Pharmaceutical Products stocks.
- INFI, NLTX, and LCTX are the stocks whose asset turnover ratios are most correlated with ATHX.
The table below shows ATHX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.020 | 1 | 7.687 |
| 2021-03-31 | 0.020 | 1 | 6.179 |
| 2020-12-31 | 0.023 | 1 | 6.796 |
| 2020-09-30 | 0.008 | 1 | 7.038 |
| 2020-06-30 | 0.000 | 1 | 6.688 |
| 2020-03-31 | 0.092 | 1 | 6.754 |
ATHX Price Target
For more insight on analysts targets of ATHX, see our ATHX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.75 | Average Broker Recommendation | 1.38 (Strong Buy) |
ATHX Stock Price Chart Interactive Chart >
ATHX Price/Volume Stats
| Current price | $1.57 | 52-week high | $33.25 |
| Prev. close | $1.39 | 52-week low | $0.50 |
| Day low | $1.39 | Volume | 500,300 |
| Day high | $1.57 | Avg. volume | 362,222 |
| 50-day MA | $0.87 | Dividend yield | N/A |
| 200-day MA | $4.80 | Market Cap | 17.28M |
Athersys, Inc. (ATHX) Company Bio
Athersys, Inc. focuses on the research and development activities in the field of regenerative medicine. The company was founded in 1995 and is based in Cleveland, Ohio.
Latest ATHX News From Around the Web
Below are the latest news stories about ATHERSYS INC that investors may wish to consider to help them evaluate ATHX as an investment opportunity.
Athersys shares take a wild ride while executives meet with investorsIf the company's stock price stays above $1 for 10 consecutive business days, Athersys will regain compliance with a Nasdaq listing requirement. |
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in JanuaryCLEVELAND, January 11, 2023--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK. |
Athersys shares rise as company managers meet with investorsFor most of the last year, clinical-stage Athersys has been cutting costs to preserve its capital while looking for new partners to help launch its adult stem cell therapy. |
Athersys Provides MultiStem Clinical UpdateCLEVELAND, January 09, 2023--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inf |
Athersys appoints biotech veteran to board of directorsAthersys Inc., the regenerative medicine startup in Cleveland, has appointed a biotech and drug commercialization professional to its board of directors. Joseph Nolan is CEO of Jaguar Gene Therapy LLC in Lake Forest, Illinois, Athersys said in a statement. "Joe is a strong addition to our board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations," Ismail Kola, chairman of the Athersys board, in the company's statement. |
ATHX Price Returns
| 1-mo | 86.90% |
| 3-mo | -39.85% |
| 6-mo | -75.50% |
| 1-year | -92.68% |
| 3-year | -95.48% |
| 5-year | -96.49% |
| YTD | 86.90% |
| 2022 | -96.28% |
| 2021 | -48.42% |
| 2020 | 42.28% |
| 2019 | -14.58% |
| 2018 | -20.44% |
Continue Researching ATHX
Here are a few links from around the web to help you further your research on Athersys Inc's stock as an investment opportunity:Athersys Inc (ATHX) Stock Price | Nasdaq
Athersys Inc (ATHX) Stock Quote, History and News - Yahoo Finance
Athersys Inc (ATHX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...